{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015232","form_type":"8-K","ticker":"AMWL","cik":"0001393584","company_name":"American Well Corp","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.039476+00:00","generated_at":"2026-06-06T02:11:14.433975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amwell Q4 revenue $70.7M; net loss narrows to $50M; guides to 2026 EBITDA breakeven","bullets":["Q4 2023 total revenue $70.7M (subscription $27.3M, AMG visits $32.1M); gross margin 34%.","Q4 net loss $50.0M vs Q3 $137.1M (Q3 included $78.9M goodwill impairment); adjusted EBITDA -$36.9M.","Full-year 2023 revenue $259M; net loss $679.2M (includes $436.5M goodwill impairment); adj. EBITDA -$165.4M.","FY2024 guidance: revenue $259-269M, AMG visits 1.6-1.7M, adj. EBITDA -$160M to -$155M.","Preliminary FY2025: revenue $335-350M, adj. EBITDA -$45M to -$35M; target adj. EBITDA breakeven by 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015232","json":"https://secwatch.observer/filing/0000950170-24-015232.json","markdown":"https://secwatch.observer/filing/0000950170-24-015232.md","text":"https://secwatch.observer/filing/0000950170-24-015232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393584/000095017024015232/0000950170-24-015232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393584/000095017024015232/amwl-20240214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:11:14.433975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d0f468ba8c9bd6cc77442ecba109c349171db3e","claim":"American Well Corp reported fourth quarter and full year ended December 31, 2023 results: revenue Total Revenue of $70.7 million, net income Net loss was ($50.0) million.","evidence_excerpt":"With the achievements of 2023, we begin 2024 with high conviction regarding our path to profitability.” Amwell Fourth Quarter 2023 Highlights: • Recorded Total Revenue of $70.7 million o Achieved subscription revenue of $27.3 million o Recorded Amwell Medical Group (“AMG”) visit revenue of $32.1 million • Reported gross margin of 34% • Net loss was ($50.0)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393584/000095017024015232/0000950170-24-015232-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Total Revenue of $70.7 million"},{"label":"Net income","value":"Net loss was ($50.0) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}